1 The Heart Centre, Copenhagen University Hospital, Denmark.
2 Department of Cardiology, Herlev and Gentofte University Hospital, Denmark.
Eur J Cardiovasc Nurs. 2019 Feb;18(2):96-105. doi: 10.1177/1474515118794598. Epub 2018 Aug 17.
Although highly effective in preventing arrhythmic death, there is a high prevalence of anxiety, depression and reduced quality of life among patients who have received an implantable cardioverter defibrillator (ICD). Whether mortality, ICD shock and readmission are predicted by patient-reported outcomes is unknown.
The aim of this study was to describe patient-reported outcomes among patients with ICDs compared by: ICD indication and generator type (ICD or cardiac resynchronisation therapy ICD), and to determine whether patient-reported outcomes at discharge predict mortality, ICD therapy and readmission.
A national cross-sectional survey at hospital discharge ( n=998) with register follow-up. Patient-reported outcomes included the Hospital Anxiety and Depression Scale, Short Form-12, HeartQoL, EQ-5D and Edmonton Symptom Assessment Scale. Register data: ICD therapy, readmissions and mortality within one year following discharge.
Patients with primary prevention ICDs had significantly worse patient-reported outcomes at discharge than patients with secondary prevention ICDs. Likewise, patients with cardiac resynchronisation therapy ICDs had significantly worse patient-reported outcomes at discharge than patients without cardiac resynchronisation therapy. One-year mortality was predicted by patient-reported outcomes, with the highest hazard ratio (HR) being anxiety (HR 2.02; 1.06-3.86), but was not predicted by indication or cardiac resynchronisation therapy. ICD therapy and ventricular tachycardia/ventricular fibrillation were not predicted by patient-reported outcomes, indication or cardiac resynchronisation therapy. Overall, patient-reported outcomes predicted readmissions, e.g. symptoms of anxiety and depression predicted all readmissions within 3 months (HR 1.50; 1.13-1.98) and 1.47 (1.07-2.03), respectively).
Patients with primary indication ICDs and cardiac resynchronisation therapy ICDs report worse patient-reported outcomes than patients with secondary indication and no cardiac resynchronisation therapy. Patient-reported outcomes such as mental health, quality of life and symptom burden predict one-year mortality and acute and planned hospital readmissions.
尽管植入式心脏复律除颤器(ICD)在预防心律失常性死亡方面非常有效,但接受 ICD 治疗的患者中普遍存在焦虑、抑郁和生活质量下降的情况。患者报告的结果是否可以预测死亡率、ICD 电击和再入院尚不清楚。
本研究旨在描述 ICD 患者的患者报告结果,比较的因素包括:ICD 适应证和发生器类型(ICD 或心脏再同步治疗 ICD),并确定出院时的患者报告结果是否可以预测死亡率、ICD 治疗和再入院。
在出院时进行了一项全国性的横断面调查(n=998),并进行了登记随访。患者报告的结果包括医院焦虑抑郁量表、简短形式-12 量表、心脏生活质量问卷、EQ-5D 和埃德蒙顿症状评估量表。登记数据:出院后一年内的 ICD 治疗、再入院和死亡率。
与二级预防 ICD 患者相比,一级预防 ICD 患者的出院时患者报告结果明显更差。同样,与没有心脏再同步治疗的患者相比,具有心脏再同步治疗 ICD 的患者的出院时患者报告结果也明显更差。患者报告的结果可以预测一年死亡率,焦虑的最高风险比(HR)最高(HR 2.02;1.06-3.86),但不能通过适应证或心脏再同步治疗来预测。ICD 治疗和室性心动过速/心室颤动不能通过患者报告的结果、适应证或心脏再同步治疗来预测。总的来说,患者报告的结果预测了再入院,例如焦虑和抑郁症状预测了 3 个月内的所有再入院(HR 1.50;1.13-1.98)和 1.47(1.07-2.03)。
具有一级适应证 ICD 和心脏再同步治疗 ICD 的患者比具有二级适应证和没有心脏再同步治疗的患者报告的患者报告结果更差。心理健康、生活质量和症状负担等患者报告的结果可以预测一年死亡率以及急性和计划性住院再入院。